Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP David Altshuler sold 2,125 shares of the business’s stock in a transaction on Tuesday, August 28th. The stock was sold at an average price of $181.89, for a total value of $386,516.25. Following the transaction, the executive vice president now directly owns 41,238 shares of the company’s stock, valued at $7,500,779.82. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Shares of Vertex Pharmaceuticals stock traded down $1.73 on Friday, hitting $184.30. The stock had a trading volume of 17,194 shares, compared to its average volume of 925,282. Vertex Pharmaceuticals Incorporated has a 52-week low of $136.50 and a 52-week high of $186.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.55 and a current ratio of 3.67. The company has a market capitalization of $46.22 billion, a P/E ratio of 231.00, a PEG ratio of 1.84 and a beta of 1.48.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, July 25th. The pharmaceutical company reported $0.94 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.40 by $0.54. Vertex Pharmaceuticals had a return on equity of 19.86% and a net margin of 15.84%. The business had revenue of $752.20 million during the quarter, compared to the consensus estimate of $680.86 million. During the same period in the previous year, the business earned $0.39 EPS. The business’s quarterly revenue was up 38.2% on a year-over-year basis. analysts forecast that Vertex Pharmaceuticals Incorporated will post 2.48 earnings per share for the current year.

Several research analysts recently commented on the company. Zacks Investment Research cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Argus boosted their target price on Vertex Pharmaceuticals to $200.00 and gave the stock an “average” rating in a research note on Tuesday. They noted that the move was a valuation call. Stifel Nicolaus boosted their target price on Vertex Pharmaceuticals from $182.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, August 7th. Citigroup boosted their target price on Vertex Pharmaceuticals from $203.00 to $206.00 and gave the stock a “buy” rating in a research note on Monday, July 30th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $203.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, July 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-two have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $195.79.

Several institutional investors have recently bought and sold shares of the company. Schroder Investment Management Group lifted its holdings in shares of Vertex Pharmaceuticals by 7.3% in the 2nd quarter. Schroder Investment Management Group now owns 27,309 shares of the pharmaceutical company’s stock valued at $4,031,000 after purchasing an additional 1,849 shares during the last quarter. Bain Capital Public Equity Management LLC lifted its holdings in shares of Vertex Pharmaceuticals by 168.8% in the 2nd quarter. Bain Capital Public Equity Management LLC now owns 241,408 shares of the pharmaceutical company’s stock valued at $41,030,000 after purchasing an additional 151,614 shares during the last quarter. Advisors Asset Management Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 21.1% in the 2nd quarter. Advisors Asset Management Inc. now owns 15,434 shares of the pharmaceutical company’s stock valued at $2,623,000 after purchasing an additional 2,694 shares during the last quarter. HighPoint Advisor Group LLC purchased a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $864,000. Finally, Senator Investment Group LP lifted its holdings in shares of Vertex Pharmaceuticals by 80.2% in the 2nd quarter. Senator Investment Group LP now owns 720,000 shares of the pharmaceutical company’s stock valued at $122,371,000 after purchasing an additional 320,483 shares during the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

See Also: Market Capitalization and Individual Investors

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.